AUS
NZ
UK
CA
USA
IND
Highlights
ASX healthcare shares remain under pressure after a prolonged 2026 downturn across the sector.
ResMed Inc (ASX:RMD) has attracted attention as valuations reset across global healthcare names.
Investors are reassessing whether defensive healthcare positioning is nearing a sentiment shift.
ASX healthcare stocks remain under pressure, with ResMed (ASX:RMD) at the centre of valuation discussions as investors reassess sector positioning and long-term growth outlook.
Australian equities have entered a period of sector divergence, with healthcare stocks drawing renewed scrutiny after a prolonged stretch of underperformance. Within the broader ASX 200, the healthcare segment has been one of the weakest performers through 2026, as capital rotated toward resources and energy-linked sectors.
At the centre of this reassessment is ResMed Inc (ASX:RMD), a global leader in sleep and respiratory care technology. The company has become a focal point for market participants assessing whether deeply discounted healthcare valuations signal a turning point or simply reflect ongoing sector-wide caution.
Sector weakness reshapes sentiment
The healthcare sector’s extended decline has been driven by a combination of earnings revisions, shifting investor allocation, and broader macro uncertainty. Many large-cap healthcare names have experienced sustained pressure, contributing to a sentiment reset across the entire segment.
This broad-based weakness has created a scenario where valuation levels across multiple companies have compressed simultaneously. While individual company performance varies, the overall direction has been influenced heavily by sector rotation trends within the ASX 200.
As a result, healthcare is now being viewed through a value lens rather than a growth premium lens, marking a significant shift in market perception.
ResMed at the centre of valuation debate
ResMed Inc (ASX:RMD), a global medical device company specialising in sleep apnoea and respiratory care solutions, has become one of the most closely watched names in the sector.
The company’s position is unique within the healthcare landscape due to its established global footprint and recurring revenue base. Despite this, its share performance has reflected broader sector weakness, leading to increased focus on valuation levels relative to historical averages.
Market participants are now assessing whether the current pricing reflects temporary sector sentiment or a more structural reassessment of healthcare growth expectations.
Structural strengths in a pressured sector
Despite sector-wide weakness, ResMed’s underlying business model remains anchored in long-term healthcare demand drivers. Ageing populations, increased diagnosis rates, and rising awareness of sleep-related disorders continue to support the broader addressable market.
Unlike early-stage biotech firms, ResMed operates with an established commercial footprint, generating recurring demand from existing patient bases. This structural stability has made it a key reference point for evaluating the broader healthcare segment.
Within the Healthcare Stocks category, companies with durable revenue models have increasingly attracted attention as valuation resets continue across the sector.
Why healthcare has lagged other sectors
One of the defining themes of 2026 has been the rotation of capital into cyclical and commodity-linked sectors. Energy and materials have attracted stronger inflows, while defensive sectors such as healthcare have faced sustained outflows.
This rotation has contributed to the relative underperformance of healthcare names across the market. Even companies with stable earnings profiles have been impacted by broader sentiment shifts rather than individual operational deterioration. As a result, healthcare stocks have moved from premium positioning to value-oriented discussions within the market narrative.
Valuation compression across major names
Across the sector, valuation compression has been widespread. Many established healthcare companies now trade at levels that reflect cautious earnings expectations and reduced growth assumptions.
This environment has led to increased scrutiny of whether current pricing adequately reflects long-term fundamentals. In some cases, valuation resets have occurred more rapidly than underlying business performance changes.
ResMed Inc (ASX:RMD) has emerged as a central case study in this broader debate due to its global scale and established commercial model.
Defensive appeal versus cyclical rotation
Healthcare has traditionally been viewed as a defensive sector, offering stability during periods of market volatility. However, the recent cycle has challenged this perception as sector-specific factors have outweighed defensive characteristics.
The rotation toward cyclical sectors has reduced demand for defensive exposure, contributing to sustained pressure on healthcare equities. This shift has been particularly visible across large-cap names within the index. Despite this, defensive characteristics remain structurally intact, leading to ongoing debate about whether current pricing represents an overcorrection.
Market focus shifts toward earnings stability
As sentiment stabilisation discussions emerge, attention is turning toward earnings consistency across the healthcare sector. Investors are increasingly focused on whether revenue streams remain stable enough to support long-term valuations.
For companies like ResMed Inc (ASX:RMD), recurring revenue models and global demand exposure provide a foundation for earnings visibility. This contrasts with more cyclical sectors where earnings are more sensitive to short-term macro conditions. Within the broader ASX 200, earnings stability is becoming a key factor in determining sector rotation outcomes.
Signs of early sentiment stabilisation
While the healthcare sector remains under pressure, there are early signs that sentiment may be stabilising. Reduced selling pressure in some large-cap names suggests that valuation levels are beginning to attract attention from longer-term allocators.
However, any sustained recovery would likely depend on broader market conditions, including sector rotation patterns and macroeconomic stability.
Healthcare remains in a transition phase, where sentiment has shifted faster than fundamentals in many cases.
Long-term outlook shaped by structural demand
Despite near-term volatility, long-term structural drivers for healthcare remain intact. Ageing demographics, chronic disease prevalence, and technological innovation continue to support demand across multiple subsectors.
Companies with established global platforms are generally better positioned to benefit from these trends over time. ResMed Inc (ASX:RMD) remains one of the key examples of this structural positioning within the global healthcare landscape.
The challenge for the sector lies in reconciling long-term demand strength with short-term market sentiment.
Closing view: recalibration phase continues
The Australian healthcare sector is currently undergoing a period of recalibration, where valuation compression and sentiment shifts are redefining market perception. While ResMed Inc (ASX:RMD) has emerged as a focal point in this discussion, broader sector dynamics remain the dominant driver.
As capital flows continue to shift across the ASX 200, healthcare stocks are likely to remain in focus as investors reassess the balance between defensive characteristics and growth expectations.
